Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Incidence peaks in individuals over 70 years of age (3.06/100,000). 6 The Carney triad, caused by mutation of the SDH gene, is a rare, nonhereditary condition characterized by the presence of 3 ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData, Phase II drugs for Gastrointestinal Stromal ...

A multidisciplinary approach is crucial for managing GIST, involving surgical, medical, and potentially targeted therapies. For patients with gastrointestinal stromal tumors with liver metastases, ...

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...

GSK acquires IDRx for $1 billion upfront, with $150M milestone payments; gains lead molecule IDRX-42 for gastrointestinal stromal tumors. IDRX-42 shows 53% ORR in 1 prior therapy line, targeting ...

Cervical cancer remains a major health threat for women globally, with the highest incidence in developing nations. Despite the availability of preventive measures, challenges such as limited health ...

AI Innovation Unlocks Non-Surgical Way to Detect Brain Cancer Spread Jan. 14, 2025 — Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain ...

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors. GSK ...